# Aarti Drugs share price today (Aarti Drugs Ltd, NSE: AARTIDRUGS)

> Aarti Drugs share price today: ₹466.30 at the NSE close on 3 November 2026, down 5.0% in a year. Aarti Drugs (NSE: AARTIDRUGS) is worth ₹4,258 crore, trades at a P/E of 22.1 and has closed between ₹330.70 and ₹491.45 over the past 52 weeks. > Aarti Drugs Ltd's earnings have grown faster than its share price. Earnings per share grew +16.0% in a year while the price moved −5.0%. AARTIDRUGS · Pharma - API · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/aarti-drugs-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹466.30 (−5.0% in a year)
- P/E: 22.1× (higher than 58% of the last 11 years)
- Revenue (Jun 2026): ₹703 Cr (+19.0% on a year ago)
- Profit (Jun 2026): ₹50.0 Cr (−7.4% on a year ago)
- Operating margin: 14.0% (+1.0 points on a year ago)
- ROCE: 12%, FY26
- ROIC: 11.8%, against a 12.0% cost of capital: −0.2 points

The main question: promoters moved −1.6 percentage points over 8 quarters while the business went the other way. ## What is the Aarti Drugs share price today? Aarti Drugs Ltd's share price was ₹466.30 at the close on 3 November 2026. It has been rising for 10 weeks. That is 14.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹331 and ₹491, and at that close it sat 84% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 11 years the share price moved +283% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Aarti Drugs this quarter? One change stood out: revenue up on a year earlier for 6 quarters in a row. 1. Revenue up on a year earlier for 6 quarters in a row In the June 2026 quarter revenue was ₹703 crore, +19% on a year earlier. Why: Revenue rose because the company got better prices for its main drug ingredients and sold more of them. Next results: check whether customer inventories reset and volume growth improves. From the earnings call on 3 Aug 2026. ## What are Aarti Drugs' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Aarti Drugs reported revenue of ₹703 crore, up 19.0% from ₹591 crore a year earlier, and a profit of ₹50.0 crore, down 7.4% from ₹54.0 crore. ### Aarti Drugs results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹703 crore | ₹591 crore | +19.0% |
| Profit | ₹50.0 crore | ₹54.0 crore | −7.4% |
| Earnings per share | ₹5.50 | ₹5.91 | −6.9% |
| Operating margin | 14.0% | 13.0% | +1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Aarti Drugs' management discussed these results on a call held on 3 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Aarti Drugs share price history? Aarti Drugs closed at ₹466.30 on 3 November 2026, down 5.0% from ₹491.10 a year earlier (31 October 2025) and down 19.2% over five years. Its highest weekly close since March 2016 was ₹984.40 on 9 October 2020. ### Aarti Drugs share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹374.00 | +24.7% |
| 1 month ago · 1 Oct 2026 | ₹422.05 | +10.5% |
| 6 months ago · 30 Apr 2026 | ₹376.30 | +23.9% |
| 1 year ago · 31 Oct 2025 | ₹491.10 | −5.0% |
| 3 years ago · 3 Nov 2023 | ₹460.05 | +1.4% |
| 5 years ago · 4 Nov 2021 | ₹576.80 | −19.2% |
| 10 years ago · 4 Nov 2016 | ₹153.88 | +203.0% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹121.85 | +282.7% |
| Highest weekly close since March 2016 · 9 Oct 2020 | ₹984.40 | −52.6% |
| Lowest weekly close since March 2016 · 13 Sep 2019 | ₹109.76 | +324.8% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹491.45 | −5.1% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹330.70 | +41.0% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Aarti Drugs? 3 Nov 2026: Aarti Drugs closed at ₹466.30, up 24.7% on the week and up 10.5% on the month. 3 Aug 2026: Aarti Drugs held its results call for April to June 2026. Management guided: 15.0% consolidated operating margin once greenfield utilization improves and salicylic drag reduces; the current underlying level was described as achievable. ### Earlier

- Results for April to June 2026: Revenue up 19.0% and profit down 7.4% on a year earlier. - 9 Feb 2026: ex-date for an interim dividend of ₹2 a share. ## What dividend does Aarti Drugs pay? Aarti Drugs paid ₹2 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.43% at the ₹466.30 close on 3 November 2026. The last was an interim dividend of ₹2 a share, ex-date 9 February 2026. ### Aarti Drugs dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 9 Feb 2026 | ₹2 | Interim | same day |
| 4 Feb 2025 | ₹1 | Interim | same day |
| 6 Feb 2024 | ₹1 | Interim | same day |
| 8 Feb 2023 | ₹1 | Interim | same day |
| 9 Feb 2022 | ₹1 | Interim | 10 Feb 2022 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Aarti Drugs Ltd paid out 9% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Aarti Drugs management say on the latest results call? On the call for April to June 2026, held on 3 August 2026, Aarti Drugs' management guided: 15.0% consolidated operating margin once greenfield utilization improves and salicylic drag reduces; the current underlying level was described as achievable. > “The US market has not started yet, but business development has already started. We have already sent samples to customers for approval.”
> Adish Patil, on the call for April to June 2026

### What management guided

- Volume growth of 10.0-15.0% over the next 2 years; 10.0% remains achievable without salicylic derivatives. - Sarigam Metformin capacity to scale from 1,400 to 2,200 tons per month, including 500-550 USFDA capacity; construction takes 10-12 months and first US supplies are expected after 18-24 months. - Specialty chemicals performance is expected to repeat and improve through the remaining quarters; Sayakha captive consumption should reach 80.0-90.0% by the September and December quarters, adding about 1.0% to gross contribution at peak utilization. - Baddi solid-dosage capacity is expected to nearly double; adjacent E22 USFDA capacity should more than double through 3 multipurpose lines of about 10 tons per month each; Phase 1 and Phase 2 asset turnover is expected at 1.5x and 3.0-4.0x over the next 2-3 years. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/2648/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 3 August 2026.)

## What to watch in Aarti Drugs' next results? When Aarti Drugs reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Sayakha operating streamlining and utilization ramp - check whether captive integration advances without interruption. - What to check (from the call)
- Sayakha operating streamlining and utilization ramp - check whether captive integration advances without interruption. - Salicylic acid and derivative trials - check for commercial ramp and reduced drag at the site. - API price normalization - check whether customer inventories reset and volume growth improves. - E-22 customer approvals - check for first US commercial supply after samples and vendor onboarding. ## Which stock lists is Aarti Drugs on? Aarti Drugs is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 4141.75919117647](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 4141.75919117647](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Aarti Drugs profitable? Aarti Drugs Ltd earned ₹50.0 Cr of net profit in the Jun 2026 quarter, −7.4% on the same quarter a year earlier. Full-year FY26 profit was ₹195 Cr. Over 10 years profit has grown 10.9% a year on average. That is 7.1% of the quarter's revenue. The same quarter a year earlier earned ₹54.0 Cr. For the full year, FY26 profit was ₹195 Cr (+16.1% on the year before). Why profit moved: revenue changed +19.0% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +4.8% and revenue +10.7%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Aarti Drugs make, and is it growing? Aarti Drugs Ltd reported ₹703 Cr of revenue in the Jun 2026 quarter, +19.0% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 8.4% a year on average. The last full year, FY26, came in at ₹2,565 Cr. The last four reported quarters add to ₹2,678 Cr. FY26 revenue was ₹2,565 Cr, +7.5% on the year before. Recent pace: the last four quarters grew +10.7% on average, against 8.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.5%, against +5.1% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +1.1%, against +10.3% a year (rolling over). ## How much of every ₹100 of sales does Aarti Drugs keep? Aarti Drugs Ltd's operating margin was 14.0% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 11.0% and 20.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.4 percentage points on the year while gross margin changed +2.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Aarti Drugs' profit turning into cash? Over the last 3 years, 160% of Aarti Drugs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹254 Cr of operating cash against ₹195 Cr of profit. After ₹171 Cr of spending on assets, ₹83.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 160% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 3.4× depreciation over three years. The next section checks what that spending is building. ## Where does Aarti Drugs' cash go? Aarti Drugs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 121 days in FY26, up from 118 days in FY21. It spent ₹588 Cr on assets over the last 3 years. Customers take 118 days to pay, and stock sits for 112 days on average. At FY26 sales of ₹2,565 Cr, each day of that cycle ties up about ₹7.0 Cr, so roughly ₹850 Cr is tied up in the business at any time. FY26: customers took 118 days to pay and stock sat for 112 days, about 3.7 months of sales sitting as stock, for a full cycle of 121 days, longer than FY21's 118. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 112 days. Customers pay about 118 days after that. Suppliers are paid at 109 days. Together that makes the 121-day cycle. Spending on assets: ₹588 Cr over the last 3 years, against ₹174 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹214 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Aarti Drugs' P/E ratio, and how does it compare with its own history? Aarti Drugs Ltd's P/E is 22.1×, in the middle of its own history: higher than 58% of past readings. Its usual P/E (the middle reading) is 20.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +16.0% while the price moved −5.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −4.2% a year; about −1.5% a year came from earnings growth and about −2.7 percentage points from the multiple (the market paying less); over 10 years the price moved +11.7% a year; about +10.2% a year came from earnings growth and about +1.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Aarti Drugs business getting better or worse? Aarti Drugs Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 14.4%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Aarti Drugs earn on its capital? Aarti Drugs Ltd earned a ROCE of 12% in FY26. Its return on capital used (ROIC) is 0.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 7.6% net margin and 0.91× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.6% net margin × 0.91× asset turnover × 1.82× leverage (assets divided by equity) ≈ 12.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 11.8% − 12.0% = −0.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Aarti Drugs have too much debt? Aarti Drugs Ltd has total debt of ₹577 Cr against shareholder equity of ₹1,549 Cr as of Jun 2026, so its debt is 0.37× its equity. Year by year, that ratio went from 0.52 in FY22 to 0.37 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Aarti Drugs shareholding pattern? Domestic institutions raised their stake in Aarti Drugs Ltd by 2.4 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 10.2% of the company. Promoters moved −1.6 points over the same period, to 54.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +2.4 points over 8 quarters, to 10.2%; Promoters: −1.6 points over 8 quarters, to 54.1%; Foreign institutions: −0.2 points over 8 quarters, to 2.3%. Why the owners changed: domestic institutions drove it (+2.4 points), with the other side taken by promoters (−1.6 points). They raised their stake step by step. ## How far is Aarti Drugs from balance-sheet trouble? For Aarti Drugs Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Aarti Drugs rank in its industry? 50.1 out of 100, rank 8 of 14 in Pharma - API, with 96% of the evidence available. Aarti Drugs Ltd scores 50.1 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 8. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 16.5 + 13.4 + 8.2 + 12 = 50.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Aarti Drugs compared with? Aarti Drugs ranks 8 of 14 Pharma - API companies on the 4-Factor Sector Score, with 50.1 out of 100. 1. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ANUHPHR · breaking out · Evidence leans up · 100% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 14.9% · Operating margin 9% · 100% evidence Valuation 17.8/20 · P/E 18.3× · PEG 0.31 · 100% evidence Relative strength 11.5/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year -3.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 13.8 + 17.8 + 11.5 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% · Operating margin 30% · 76% evidence Valuation 9.2/20 · P/E 39.1× · PEG n/a · 15% evidence Relative strength 7.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 12.6% · 1 year 47% · 100% evidence · 7 of 12 weeks ahead Exact sum: 28.2 + 16.4 + 9.2 + 7.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Evidence leans up · 96% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 34.4% · Profit 18.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.0/25 · ROCE 15% · Operating margin 16% · 100% evidence Valuation 7.3/20 · P/E 38.1× · PEG 4.06 · 100% evidence Relative strength 15.8/20 · Lead over its industry 3.4% · Lead over NIFTY 500 25.3% · 1 year 23.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 13 + 7.3 + 15.8 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) BETA · losing its lead · Evidence leans up · 67% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% · Operating margin 22% · 76% evidence Valuation 8.0/20 · P/E 38.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Lead over its industry n/a · Lead over NIFTY 500 11.2% · 1 year -3.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 18.4 + 8 + 10.5 = 56.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) INDSWFTLAB · leader · Evidence leans up · 82% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% · Operating margin 19% · 76% evidence Valuation 7.1/20 · P/E 34.9× · PEG n/a · 50% evidence Relative strength 20.0/20 · Lead over its industry 71.6% · Lead over NIFTY 500 98.2% · 1 year 257.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 8.3 + 7.1 + 20 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) WANBURY · quiet · Evidence leans up · 81% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 3.6% · Profit 30% · Operating margin change -5.2 points · 88% evidence Capital efficiency 16.6/25 · ROCE 30.7% · Operating margin 9.8% · 100% evidence Valuation 19.2/20 · P/E 11.2× · PEG 0.34 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -27.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12 + 16.6 + 19.2 + 7.5 = 55.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) GUJTHEM · turning · Evidence leans up · 89% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 16.1% · Profit 6.7% · Operating margin change 9 points · 88% evidence Capital efficiency 18.1/25 · ROCE 18.1% · Operating margin 48% · 100% evidence Valuation 10.3/20 · P/E 97.1× · PEG 1.33 · 65% evidence Relative strength 7.2/20 · Lead over its industry -16.3% · Lead over NIFTY 500 3.7% · 1 year -21.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.6 + 18.1 + 10.3 + 7.2 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. Aarti Drugs Ltd this page AARTIDRUGS · turning · Evidence leans up · 96% evidence 50.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue 10.5% · Profit 1.1% · Operating margin change 1 points · 88% evidence Capital efficiency 13.4/25 · ROCE 12% · Operating margin 14% · 100% evidence Valuation 8.2/20 · P/E 20.6× · PEG 3.2 · 100% evidence Relative strength 12.0/20 · Lead over its industry -6.8% · Lead over NIFTY 500 15.8% · 1 year -11.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.5 + 13.4 + 8.2 + 12 = 50.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · breaking out · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 19.1/25 · ROCE 22.7% · Operating margin 21% · 100% evidence Valuation 6.4/20 · P/E 30.2× · PEG 3.39 · 100% evidence Relative strength 6.4/20 · Lead over its industry -10.7% · Lead over NIFTY 500 9.9% · 1 year -2.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 14.6 + 19.1 + 6.4 + 6.4 = 46.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · breaking out · Evidence leans down · 85% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% · Operating margin 22% · 100% evidence Valuation 2.9/20 · P/E 30.4× · PEG 5.52 · 100% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 22.9% · 1 year 2.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 12.4 + 2.9 + 11.8 = 44.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) FERMENTA · losing its lead · Evidence leans down · 64% evidence 42.8 out of 100 Growth Capital Valuation Relative
12. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) KOPRAN · breaking out · Evidence leans down · 81% evidence 41.5 out of 100 Growth Capital Valuation Relative
13. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ORCHPHARMA · losing its lead · Evidence leans down · 66% evidence 37.8 out of 100 Growth Capital Valuation Relative
14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 30.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Aarti Drugs in size? Aarti Drugs is the 6th largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Senores Pharmaceuticals, Orchid Pharma and Gujarat Themis Biosyn. Just below it: Ind-Swift Laboratories, Beta Drugs and Jagsonpal Pharmaceuticals. ### Pharma - API companies close in size

1. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) ₹5,222 crore
2. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ₹5,009 crore
3. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) ₹4,727 crore
4. Aarti Drugs Ltd ₹3,972 crore
5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) ₹3,202 crore
6. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) ₹2,000 crore
7. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) ₹1,427 crore

[All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies)

### Companies close in size in other industries

1. [Texmaco Rail & Engineering Ltd](https://www.sectoralpha.in/stocks/texmaco-rail-engineering-ltd) ₹3,998 crore · Railways
2. [Gujarat Alkalies & Chemicals Ltd](https://www.sectoralpha.in/stocks/gujarat-alkalies-chemicals-ltd) ₹3,975 crore · Chemicals - Inorganic - Caustic Soda/Soda Ash
3. Aarti Drugs Ltd ₹3,972 crore
4. [MPS Ltd](https://www.sectoralpha.in/stocks/mps-ltd) ₹3,970 crore · E-Commerce - Platform - Utility
5. [Sustainable Energy Infra Trust](https://www.sectoralpha.in/stocks/sustainable-energy-infra-trust) ₹3,969 crore · Infrastructure Investment Trusts

## What else do people ask about Aarti Drugs? ### What is Aarti Drugs's share price today? Aarti Drugs Ltd's share price is ₹466.30, −5.0% over the past year. The whole company is worth ₹4,258 Cr on the market. In the last 52 weeks it traded between ₹331 to ₹491; today it is 84% of the way up from the low, 14.4% above its 200-day average (as of 3 November 2026). ### What were Aarti Drugs's latest quarterly results? Aarti Drugs Ltd reported revenue of ₹703 Cr and net profit of ₹50.0 Cr for the Jun 2026 quarter. Revenue rose 19.0% and profit fell 7.4% compared with a year earlier. Earnings per share were ₹5.50. The operating margin was 14.0%, 1.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Aarti Drugs's market cap? Aarti Drugs Ltd's market capitalisation is ₹4,258 Cr at a share price of ₹466.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Aarti Drugs performing? Aarti Drugs Ltd's share price has been rising for 10 weeks. In its latest quarter, revenue rose 19.0% and profit fell 7.4% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Aarti Drugs's share price go up? This page does not forecast Aarti Drugs Ltd's share price. What it shows instead: the share price is ₹466.30, and it has been rising for 10 weeks. Its P/E of 22.1× is higher than 58% of its own last 11 years (as of 3 November 2026). ### Who owns Aarti Drugs? Promoters own 54.1% of Aarti Drugs Ltd, foreign institutions 2.3%, domestic institutions 10.2% and the public 33.4% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 2.4 percentage points over 8 quarters (as of 3 November 2026). ### Where is Aarti Drugs in its business cycle? Aarti Drugs Ltd's FY26 operating margin was 12.0%, against a 13-year range of 11.0% to 20.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 14.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Aarti Drugs story? The main question: promoters moved −1.6 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Aarti Drugs a stock worth studying right now? What the numbers show: Aarti Drugs Ltd's earnings have grown faster than its share price. Earnings per share grew +16.0% in a year while the price moved −5.0%. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Aarti Drugs share price forecast for 2026? What management itself guided: 15.0% consolidated operating margin once greenfield utilization improves and salicylic drag reduces; the current underlying level was described as achievable. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.